Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by bionicjoeon Apr 06, 2019 10:40am
139 Views
Post# 29591666

RE:RE:Ph2 in Europe and US by Q3?

RE:RE:Ph2 in Europe and US by Q3?
Macer wrote:
newdaydawning wrote: As Macer reports, the new investor relations gal says we can count on a Q3 roll-out of Ph2 in Europe and US. Delighted to hear this news, but wonder how TLT can finance this ambitious international expansion of the Ph2 NMIBC trial.

Something tells me that TLT is on the verge of securing the required financing. Indeed, I would argue that the two new CEOs would not have signed on without some assurance of stable financing. So talks about new financing have likely been in the works for some tiime, and should bear fruit soon.


Just to keep things real.
I did not say I was told that we can "count" on anything.
She simply relayed targets, no gaurantees.


Haven't you guys learned anything in 5 years?

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities